Free Trial

Paradigm Biocapital Advisors LP Purchases 273,694 Shares of Vaxcyte, Inc. $PCVX

Vaxcyte logo with Medical background

Key Points

  • Paradigm Biocapital Advisors LP increased its stake in Vaxcyte, Inc. by 19.2%, now owning 1,696,481 shares which represent 3.0% of its portfolio.
  • Vaxcyte's stock is rated as a strong buy by one analyst and has a consensus rating of "Buy" with an average price target of $136.50.
  • The company reported a loss of ($1.22) EPS for the last quarter, missing analyst estimates and showing a decline from the previous year's loss of ($1.10) EPS.
  • Five stocks to consider instead of Vaxcyte.

Paradigm Biocapital Advisors LP raised its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 19.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,696,481 shares of the company's stock after acquiring an additional 273,694 shares during the period. Vaxcyte makes up 3.0% of Paradigm Biocapital Advisors LP's investment portfolio, making the stock its 10th biggest holding. Paradigm Biocapital Advisors LP owned 1.32% of Vaxcyte worth $64,059,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. AlphaQuest LLC acquired a new position in shares of Vaxcyte in the first quarter valued at approximately $33,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Vaxcyte in the first quarter valued at approximately $35,000. Parallel Advisors LLC grew its holdings in Vaxcyte by 203.6% during the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock worth $61,000 after acquiring an additional 1,071 shares during the period. IFP Advisors Inc grew its holdings in Vaxcyte by 376.4% during the first quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock worth $62,000 after acquiring an additional 1,306 shares during the period. Finally, Twin Tree Management LP grew its holdings in Vaxcyte by 301.3% during the first quarter. Twin Tree Management LP now owns 2,365 shares of the company's stock worth $89,000 after acquiring an additional 3,540 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Analyst Ratings Changes

Separately, Cowen reaffirmed a "buy" rating on shares of Vaxcyte in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $130.00.

Get Our Latest Analysis on PCVX

Vaxcyte Trading Up 3.3%

Shares of Vaxcyte stock traded up $1.05 during trading hours on Friday, reaching $33.20. 460,108 shares of the company's stock were exchanged, compared to its average volume of 1,753,458. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06. The firm has a market capitalization of $4.31 billion, a price-to-earnings ratio of -8.03 and a beta of 1.04. The company has a fifty day moving average of $33.21 and a 200-day moving average of $41.31.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the previous year, the firm posted ($1.10) earnings per share. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Company Profile

(Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Read More

Institutional Ownership by Quarter for Vaxcyte (NASDAQ:PCVX)

Should You Invest $1,000 in Vaxcyte Right Now?

Before you consider Vaxcyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.

While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.